STAT+: After Elsa, FDA rolls out \u2018agentic AI\u2019 for staff
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
You\u2019re reading the web edition of STAT\u2019s Health Tech newsletter, our guide to how technology is transforming the life sciences.\u00a0Sign up to get it<\/a>\u00a0delivered in your inbox every Tuesday and Thursday.<\/em><\/p>\n The FDA announced<\/a> it will continue its speedy push into the AI unknown with new \u201cagentic AI capabilities\u201d to support a range of regulatory work including pre-market reviews, review validation, post-market surveillance, inspections, and compliance. An agency spokesman told me<\/a> that all regulatory decisions will ultimately be in the hands of staff.\u00a0<\/p>\n You may remember that the FDA, earlier this year, launched Elsa, an LLM-based tool to support agency staff. Early users reported the errors and fabulation<\/a>s<\/a> that come along with LLM-based tech. FDA now claims over 70% of staff have used the product.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n